ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KRRO
BBOT (33) NATR (64) PYXS (27) SIGA (68) ⌘ Pro Terminal →

Korro Bio Inc. (KRRO) — RQD Stock Rating Cockpit

$15.85 +10.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.12

Korro Bio Inc. (KRRO) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $210.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KRRO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KRRO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Korro Bio Inc. (NASDAQ: KRRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $15.85 (+10.69% 1D, market cap $210.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, KRRO ranks #464 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KRRO compare to BBOT and NATR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KRRO carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BBOT (BridgeBio Oncology Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $210.1M) and NATR (Nature's Sunshine Products Inc.) posts a C grade (64/100 RQD, P/E 11.1x, ROIC 28.9%, cap $215.5M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while SIGA leads on capital efficiency (42.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KRRO?
▼

Per KRRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001703647), Korro Bio Inc. generated $6.4M in revenue (+181.5% YoY), -$117.3M in net income, and -$79.1M in free cash flow against $113.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $16.12 (+1.73%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (8)Whales (12)SEC (8)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$44 Bull$15 Base$11 Bear
📬 FREE KRRO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRRO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY KRRO SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)

FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 71.4 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
32
Grade E$8.81+7.2% Next Q
Q2 (-2Q)
35
Grade E$9.44+40.9% Next Q
Q3 (-1Q)
37
Grade E$13.30+19.2% Next Q
Current
40
Grade D-$15.85-7.4% Hist 90D α
Trajectory: E (32) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KRRO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KRRO currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.45) and Max Pain ($16.64) forces dealer call-delta covering toward $43.63.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRRO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KRRO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERBOUGHT (>70)
71.430 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE29% OF RANGE
L: $5$15.85H: $42
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on KRRO

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (40)

15/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like KRRO
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRRO)

  • ✓Walkthrough of KRRO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KRRO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.64%▲ RESISTANCE BREAKOUT
2026-11-03O $14.20H $15.85L $14.20C $15.85VOL 130.8K
RES: $14.86SUP: $8.03SMA50: $11.45SMA200: $11.99
$19.41$16.41$13.41$10.41$7.41RES $14.86SUP $8.03$15.852026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KRRO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KRRO Butterfly Map → + Track KRRO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +181.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KRRO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KRRO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KRRO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRRO)

Health Care Rank #464 of 1015 ⚔️ BBOT vs KRRO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KRRO vs. BBOT, NATR, PYXS, SIGA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Korro Bio Inc. (KRRO) ranks #464 by composite RQD confidence (40/100, grade D-) and #565 by equity capitalization ($210.8M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while SIGA leads on capital efficiency and profitability with 42.7% ROIC and 68.6% gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with KRRO at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KRRO ACTIVE
Korro Bio Inc.
D- 40/100 — — -35.0% +10.69% $210.8M Benchmark Subject
BBOT
BridgeBio Oncology Therapeutics Inc.
E 33/100 — — -35.0% -11.83% $210.1M /bbot-vs-krro →
NATR
Nature's Sunshine Products Inc.
C 64/100 11.1x 72.4% 28.9% -1.88% $215.5M /natr-vs-krro →
PYXS
Pyxis Oncology Inc.
E 27/100 — 82.8% -35.0% -6.63% $216.4M /pyxs-vs-krro →
SIGA
SIGA Technologies Inc.
C+ 68/100 9.8x 68.6% 42.7% -2.96% $218.4M /siga-vs-krro →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001703647 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Korro Bio Inc. (KRRO) reported GAAP revenue of $6.4M (+181.5% vs. FY2024 revenue of $2.3M , and -97.3% cumulative change since FY2023) , GAAP net income of -$117.3M, operating cash flow of -$78.6M, and free cash flow of -$79.1M (-1.4% YoY). On the balance sheet, KRRO closed FY2025 with $113.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.4M -$117.3M -$78.6M -$79.1M $113.5M —
FY2024 (FY) 2024-12-31 $2.3M -$83.6M -$60.1M -$78.0M $226.2M —
FY2023 (FY) 2023-12-31 $236.7M -$81.2M -$67.3M -$67.3M — —

3. KRRO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KRRO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Korro Bio Inc. (NASDAQ: KRRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $15.85 (+10.69% 1D, market cap $210.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, KRRO ranks #464 in composite RQD confidence.

How does KRRO compare to BBOT and NATR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KRRO carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BBOT (BridgeBio Oncology Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $210.1M) and NATR (Nature's Sunshine Products Inc.) posts a C grade (64/100 RQD, P/E 11.1x, ROIC 28.9%, cap $215.5M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while SIGA leads on capital efficiency (42.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KRRO?

Per KRRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001703647), Korro Bio Inc. generated $6.4M in revenue (+181.5% YoY), -$117.3M in net income, and -$79.1M in free cash flow against $113.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KRRO trading relative to its 50-day, 200-day, and 52-week technical levels?

KRRO last traded at $15.85 (+10.69% on volume of 206,772 shares), positioning the stock +38.43% above its 50-day simple moving average ($11.45) and +32.19% above its 200-day simple moving average ($11.99). Across its 52-week range of $5.20 to $41.55, KRRO sits at the 29.3% percentile with a 14-day RSI of 71.4 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($13.87 to $17.83).

Direct Sub-Reports: KRRO RQD Cockpit KRRO 12M Forecast KRRO Earnings & Move KRRO Dividends & DRIP KRRO Insiders & 13F KRRO Whale Options KRRO Profit Sankey KRRO News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

KRRO — Korro Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Korro Bio Inc. (KRRO) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $15.85 (+10.69% 1D, market capitalization $210.8M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Korro Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Korro Bio Inc. (KRRO) reported $6.4M in annual revenue (up from $2.3M in FY2024, +181.5% YoY) and -$117.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($236.7M revenue, -$81.2M net income) through FY2025, KRRO scaled operating cash flow to -$78.6M and free cash flow to -$79.1M, backed by $113.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 12/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $5.20 – $41.55 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No supply-chain dependencies, butterfly links, or proprietary signals are recorded. Upstream and downstream relationships, sector correlations, and 2nd-order bottlenecks are therefore — The only sector context provided is the Health Care / Biotechnology: Pharmaceutical Preparations classification and the RQD macro regime score, which reflects sector sensitivity but does not identify specific ripple channels.

  • Key Question #1: Can KRRO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.4M and free cash flow of -$79.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KRRO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KRRO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Korro Bio Inc. (KRRO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KRRO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KRRO Bull vs. Bear Conversation Board — What's Your Call at $15.85?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KRRO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KRRO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $18.76 (+31.0%)
📌 Pinned Debate

Institutional accumulation and a 10% owner's purchases signal active whale buying, supported by a 29.7% surge headline.

Don't sleep on KRRO's setup in Health Care. Institutional accumulation and a 10% owner's purchases signal active whale buying, supported by a 29.7% surge headline.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (40/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

@CreditSpread_Watch Shorting a 12/20 institutional whale-flow stock at $14.32 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $12.03 (-16.0%)
Spot @ $14.32

Operating losses of -$121.9M against $21.8M of cash, with ROIC at -35% and insider conviction scoring only 3 / 20.

I respect the product at Korro Bio Inc., but the stock at $14.32 is a different story. Operating losses of -$121.9M against $21.8M of cash, with ROIC at -35% and insider conviction scoring only 3 / 20.. FCF yield is 0.0% and RQD sits at 40/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%